P05-02. Including peptides-mimotopes of neutralizing 2F5 epitope of HIV-1 into artificial peptide TBI – vaccine candidate by Scherbakova, NS et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
P05-02. Including peptides-mimotopes of neutralizing 2F5 epitope 
of HIV-1 into artificial peptide TBI – vaccine candidate
NS Scherbakova*, A Chikaev, O Tumanova, L Karpenko and A Il'ichev
Address: Department of Immunotherapeutic Preparation, SRC VB "Vector", Koltsovo, Russian Federation
* Corresponding author    
Background
It is convincing evidence that anti-HIV-1 vaccine should
elicit broadly neutralizing monoclonal antibodies which
neutralize broad range of laboratory and primary isolates
of HIV-1. Artificial protein TBI (T and B cell epitopes con-
taining immunogen) which contains 4 T-cell and 5 B-cell
epitopes of HIV-1 was created in SRC VB ''Vector'' in 90-
th. Now there is a lot of new information about neutraliz-
ing epitopes of HIV-1. It has been known several mono-
clonal antibodies, which have broad neutralization
activities. 2F5 antibody recognizes a core epitope of liner
sequence ELDKWA in the ectodomain of gp41 near the
transmembrane region. Attempts to create immunogen
with natural 2F5 epitope on the basis of various vectors
were unsuccessful in the possibility to induce neutralizing
antibodies.
One of the perspective approaches in the design of vaccine
immunogens represented by phage display technique
based method of searching peptides that mimic HIV-1
epitopes.
Methods
Early in our department have been received peptides-
mimotopes of 2F5 epitope. It has been shown that mice
and rabbits immunized with those peptides elicited anti-
bodies that neutralized laboratory strains of HIV-1.
Results
Two peptides-mimotopes were introduced into artificial
TBI protein instead one of the B-cell epitope by gene engi-
neering technique.
Finally, it have been received recombinant proteins TBI-
2F5-1 and TBI-2F5-2. These recombinant peptides were
characterized by ELISA and Western blot analysis with
monoclonal antibodies to HIV-1. Results have shown that
the recombinant proteins have kept antigenic properties
of the peptides-mimotopes.
Conclusion
Thus, it have been received two recombinant proteins
keeping structure of protein TBI and antigenic properties
of the peptides-mimotopes. It has been shown that
recombinant proteins elicited HIV-specific immune
response.
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